In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant (HCT) conferred nearly universal mortality secondary to lack of consensus for diagnostic criteria, poorly understood disease pathogenesis, and very few studies of therapeutic or supportive care interventions. Recently, however, progress has been made in these areas: revised consensus diagnostic guidelines are now available; supportive care has improved; there is greater understanding of potential mechanisms of disease and prospective trials are being conducted. This article describes these advances and provides suggestions to optimize therapy for patients with BOS after HCT.
Abstract:
In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant (HCT) conferred nearly universal mortality secondary to lack of consensus for diagnostic criteria, poorly understood disease pathogenesis, and very few studies of therapeutic or supportive care interventions. Recently, however, progress has been made in these areas: revised consensus diagnostic guidelines are now available; supportive care has improved; there is greater understanding of potential mechanisms of disease and prospective trials are being conducted. This article describes these advances and provides suggestions to optimize therapy for patients with BOS after HCT.
Introduction:
Despite advances in the treatment of graft-versus-host disease (GVHD) and supportive care after HCT, lung manifestations of chronic GVHD (cGVHD) continue to confer poor prognosis.
1-3 Lung cGVHD or bronchiolitis obliterans syndrome (BOS), results from immune attack of the small airways, leading to fibrotic occlusion and subsequent obliteration. BOS is often an asymptomatic, insidious disease occurring within the first 2 years of HCT with other manifestations of cGVHD. The diagnosis relies upon obstructive decline in pulmonary function in the absence of other etiologies. Diagnosis, supportive care, and treatments for this disease have improved in recent years. Here, I
describe my approach to BOS diagnosis and treatment via discussion of illustrative cases.
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Case reports:
Case 1: Diagnostic criteria Patient 1 is a child who underwent matched sibling peripheral blood stem cell transplantation (PBSCT) for acute leukemia. Her course was complicated by cGVHD of multiple organs and declining forced expiratory volume at 1 second (FEV1) to less than 50% predicted, though ratio of FEV1/FVC (forced vital capacity) remained greater than 0.7. Inspiratory CT showed reticulonodular disease. The patient underwent right upper lobe biopsy, which was complicated by pneumothorax, pneumomediastinum, pneumatoses, and subcutaneous emphysema. Biopsy showed bronchiolitis obliterans and infectious tests were negative.
Discussion of Case 1:
As the current case highlights, lung biopsy in these patients can be associated with high morbidity.
4,5 While historically, this was the preferred method of diagnosis, now pulmonary function test (PFTs) criteria are sufficient for most patients after HCT. In the thirty-five years since the first accounts of lung cGVHD, noninvasive diagnostic criteria for BOS have been developed and refined by international consensus. [6] [7] [8] [9] The current definition of BOS includes: 1) FEV1<75% predicted and an irreversible >or = to10% decline in <2 years, 2) FEV1/VC ratio <0.7 or the lower limit of the 90% confidence (Figure 1a) . 9, 10 These new diagnostic criteria incorporated several important updates. Firstly, air trapping was no longer a required criteria for patients who had obstructive disease and cGVHD, as this finding is often absent early in the disease course.
10,11 Secondly, a standard threshold for the FEV1/FVC ratio (of 0.7) was supplemented by consideration of the normal age-adjusted confidence interval. 12 Because the ratio of young children is 1 and declines with age, both children and the elderly may be misdiagnosed using the 0.7 ratio cutoff. Patient 1 would have met criteria for BOS by PFTs alone using current definitions, using National Health and Nutrition Examination Survey equations. 13 Similarly, elderly individuals may have appropriate age-related decline in FEV1 to less than 0.7, and not de facto meet criteria for obstruction. Finally, the slow vital capacity may now be used rather than FVC, as some BOS patients require slow exhalation to reveal full VC due to early airway collapse with the forced expiratory maneuver. Patients with more severe disease may have evidence of air trapping by PFTs (elevated RV) or on expiratory CT scan (mosaic pattern); however, as suggested by the NIH 2014 guidelines, these features are not required to diagnose BOS. One final population that is particularly challenging to diagnose are those with extra-pulmonary restriction, which may be due to sclerotic GVHD of the pulmonary girdle, GVHD myositis (with elevated creatine kinase or aldolase), steroid myopathy, or polyneuritis affecting respiratory muscles. The maximum inspiratory and expiratory pressures (MIP/EP) may be a marker of muscle weakness. The extra-pulmonary restriction will also diminish total lung capacity and VC,
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It is very important to exclude other diagnoses, including idiopathic pneumonia syndrome, cryptogenic organizing pneumonia, pulmonary fibrosis and late radiation effects, infection, asthma, or chronic obstructive pulmonary disease (COPD), and rare disorders such as tracheomegaly, tracheobronchomalacia, alpha-1 antitrypsin deficiency.
Infection must be excluded to diagnose BOS and requires a thorough investigation. The FEV1 decline in asthma is reversible with albuterol in contrast to BOS. Idiopathic pneumonia syndrome typically presents earlier after transplant, and, in addition to pulmonary fibrosis, late radiation effects, should be excluded by the absence of obstruction. Tracheomegaly occurs in adulthood and is diagnosed by an enlarged trachea on CT as well as a characteristic notch in the expiratory flow volume loop (Figure 1b) . This can also be seen in tracheobronchomalacia, which can mimic BOS, and may be diagnosed by bronchoalveolar lavage (BAL).
14 Cryptogenic organizing pneumonia (COP) usually presents with restriction but a mixed picture with obstruction may be present. COP, previously termed "bronchiolitis obliterans organizing pneumonia (BOOP)" should include a new consolidation on CT and respond rapidly to steroids in contrast to BOS. Alpha-1-anti-trypsin deficiency also presents with obstructive disease, and while there is often some obstruction present pre-HCT, this may be much more perform an intensive work-up for infections, which may either cause the FEV1 decline, or often, be a co-factor. Finally, I recommend BAL, which may be critical to diagnose and help guide therapy for co-infections or colonization or resistant bacteria that may lead to subsequent infectious episodes and guide therapy, and to rule out bronchomalacia or broncho-obliterans (Figure 4 ). In the rare circumstance a diagnosis is not achieved through these methods, and the index of suspicion for infection remains high, I will pursue lung biopsy. Severity of disease may be classified by: mild FEV1 > 60%, moderate FEV1 40-59%, and severe FEV1 < 39%. and ophthalmic GVHD and a non-productive cough. Despite pulmonary symptoms, the first PFTs were administered greater than 2 years after initial cGVHD diagnosis, showed new obstruction, and were consistent with BOS with considerable FEV1 decline to 50% predicted with ratio of FEV1/VC of 0.5.
Discussion of Case 2:
This case highlights the potential benefit of frequent screening PFTs, permitting the earliest diagnosis of disease, prior to the onset of symptoms. Symptoms of BOS may include chronic non-productive cough, dyspnea on exertion, decrease in exercise tolerance, wheezing, or pneumomediastinum. Clinical symptoms of disease are often associated with moderate/severe FEV1 decline, suggesting that a window of time has already passed in which more mild obstruction might have been identified. However, this case is not unusual. A recent study of 82 patients diagnosed with BOS by current criteria showed that the median FEV1 was 53% at diagnosis and risk factors for poorer prognosis included diagnosis within one year and decreased FVC. 18 Further, as described in this manuscript, the modern trajectory of BOS is characterized by a rapid decline in
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From FEV1 followed by a period of relative stabilization, likely due to recognition and interventions. Thus, theoretically, earlier detection could lead to a plateau at a higher, and less morbid FEV1. A good way to monitor lung function is to follow the regression slope of FEV1 volume versus time (Figure 2) . The slope also removes any influence of different PFT equations, which can significantly alter FEV1 % predicted (up to 27%). 13 In addition to quickly revealing FEV1 changes, the rate of decline can be compared interpatient to compare disease severity and intra-patient to evaluate the success of therapies.
Notably, for pediatric patients, the necessity of growth is important to include, thus it is best to evaluate the % predicted slope for prognosis (showing sufficient recruitment of lung for growth). 19 For children with pneumothorax limiting PFTs, 6-minute walk assessment can be a good surrogate for progression in the absence of other cGVHD manifestations that impair mobility. Another important means to monitor these patients include the NIH cGVHD organ grading and patient reported outcome measures such as the Lee symptom scale.
9,20
PFT monitoring is especially important for patients at highest risk of BOS, including those with chronic GVHD, which doubles the incidence from 5-6% to 13%. 10, [21] [22] [23] [24] Other risk factors for BOS after HCT include: preparative regimens containing busulfan, peripheral blood stem cell source, viral infections early after HCT, history of significant acute GVHD, as seen in our patient, as well as ABO incompatibility prior lung disease, and post-transplant lung disease. [25] [26] [27] [28] [29] [30] [31] [32] Published guidelines for PFT monitoring have promoted every 3 months monitoring for a year after transplant. 33 However, given that the median diagnosis of new-onset BOS was 1.5 years from HCT, in a recent prospective Another important consideration is whether we could identify patients who have begun the pathological process of obliterative bronchiolitis prior to the severe decline of FEV1 below 75% predicted. An early stage has been defined in lung transplant BOS (host versus graft disease) and labeled BOS-0p, which identifies patients at higher risk to progress to BOS. In lung transplantation, 30% of these patients will progress to BOS.
39
A similar definition has recently been evaluated in HSCT patients. 40 BOS-0p was defined as: decline in FEV1 of >10% or midflow rate (FEF25-75) of >25 % decline and not meeting BOS criteria. 40 In HCT recipients, BOS-0p was sensitive for the development of BOS. 40 These data suggest that not only could more frequent PFTs better identify patients at highest risk for BOS progression, but also permit early interventions in a population already suffering from allo-immune bronchiole damage. Prospective studies should test whether interventions at this point can prevent BOS altogether, potentially providing the best opportunity for averting disease. At the time of autopsy, in addition to obliterative bronchiolitis, aspergillus and CMV were evident in the lungs, despite negative BAL and blood tests.
Discussion of Case 3:
This case highlights several key supportive care issues in BOS. In our prospective study NCT00656058, patients underwent extensive evaluation for infection, including bronchoalveolar lavage (n=19). All but one patient (4%) presented without evidence of infection. Despite this, 25% of patients had infections identified through BAL, including:
pseudomonas infection (n=1), mycobacteria infection (n=2), aspergillus infection (n=2), CMV pneumonitis (n=1), and nocardia (n=1). Excluding these baseline infections, a total of 45 infections were experienced in 24 patients on study, 36% bacterial (most commonly gram negative), 47% viral (most commonly influenza), 16% fungal (mostly aspergillus), and mycobacterial infection (2%). This high rate of co-infections requires vigilance on the part of the provider, as infections are a leading cause of death in these patients.
16,22,41
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The high rate of mycobacterial and nocardia infections in this patient population (21% total) deserves further consideration, and suggest that BAL should be strongly considered in patients with acute decline. This relative increase in non-tuberculous mycobacteria has been noted in lung transplant recipients and linked to BOS progression. 42 Interestingly, other bacterial infections identified were exclusively gram-negative (pseudomonas, morexella, klebsiella, E. coli, stenotrophomonas). Both these non-tuberculosis mycobacterial infections and gram-negative bacteria may be related to colonized bronchiectasis, which is often associated with BOS. 43, 44 Treatment is likely critical not just to avoid progression of infection, but these infections may incite chemokines and accelerate BOS progression and death. 45 Further, similar to patients with bronchiectasis from other causes, patients with BOS can be colonized with gram-negative organisms, and experience exacerbations similar to cystic fibrosis. I have seen benefit from inhaled aminoglycosides to constrain these organisms (typically employing a one month on and one month off approach), using spontaneous or induced sputum to follow the organism burden. In addition, early treatment with fluoroquinolones (or other sensitive antimicrobials) in the setting of sputum production and increased cough has clinically seemed beneficial for these patients. However, recommended anti-microbials for BOS patients should include prophylaxis against: pneumocystis jiroveci pneumonia (with Trimethoprim/sulfamethoxazole preferentially), Streptococcus with penicillin, and fungi
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From as described above. 46 I administer IVIG for patients with IGG less than 500mg/dL, though studies have not evaluated its benefit in BOS patients. Finally, influenza can be life-threatening in BOS patients, and prompt treatment with neuraminidase inhibitors is critical at the earliest sign of disease. Immunizations may be important to protect against these lung infections when patients are sufficiently immunocompetent. Further study of the best ways to diagnose, treat, and prevent these infectious complications will be important to improve outcomes in BOS.
It is important to note that chest x-rays may not reliably show infections in BOS patients, as the trapped air can effectively conceal even larger infiltrates, as in patient 3.
Furthermore, for infections such as mycobacteria and fungal disease, evaluation by CT is necessary to identify the minute nodules of mild disease. CTs can also show bronchiectasis, suspicious for gram-negative bacterial colonization.
Other supportive care considerations include opportunities to minimize further infectious exposures and inflammatory sources while optimizing remaining pulmonary function. Studies have suggested that gastroesophageal reflux disease (GERD) may be associated with BOS genesis and progression, and maximizing GERD therapies may diminish progression of BOS. 47, 48 Further, data in lung transplantation even support Nissen fundoplication procedures, though this has not been studied in BOS after HCT. 49 Optimization of nutrition is important and may require supplemental nutrition while treating severe BOS. Supplemental nutrition is especially important in patients with continued weight loss. For patients who have some mild benefit by increased FEV1% by more than 12% with beta-agonists, these agents may modestly increase endurance. For these patients, I initiate a trial with albuterol and may prescribe a long-acting beta-agonist
additionally. However, albuterol can also lead to bronchomalacia if over-used (due to reduced smooth muscle tone), and I have seen this occur following misdiagnosis and days of continuous albuterol. Pulmonary rehabilitation improves exercise tolerance and quality of life. 34, 50 Similarly, if patients require anti-hypertensive treatment, agents other than beta-blockers or ACE-inhibitors may be better from a pulmonary perspective.
Anemia should be corrected and patients with good hematopoiesis will often compensate with mildly elevated hemoglobin. Acute hypoxemia is a rare presentation of BOS, most often linked either to acute infection or methemoglobinemia (often associated with dapsone). Finally, should patients require ventilatory support, the pathophysiology of BOS is important to consider. Because these patients have significant air trapping and fixed small airway obstruction, additional positive pressure should be minimized as this will increase the risk of barotrama and exacerbate air-trapping. Further, the settings should reflect that patients require added time for exhalation. Tracheostomy will increase the impedance to airflow. Finally, they should be carefully monitored for hypercapnea, which can lead to life-threatening apnea in the setting of oxygen administration. 
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70% predicted and long-acting beta-agonist was started. Two months later a GVHD flare led to resumption of systemic steroids and tacrolimus and sirolimus was soon added. Six months after BOS presentation and 1.5 years after HCT, FEV1 was 45% predicted, prompting initiation of Tiotropium bromide in addition to steroids, sirolimus, tacrolimus, followed by rituximab, then soon after by radiation therapy with 1 Gy total body irradiation. At 3 years post-HCT, FEV1 had declined to 36%, with FEV1 slope of -3, despite a treatment regimen that now included mycophenylate mofetil, azithromycin, advair, tacrolimus, and he was referred for a trial of montelukast at NIH.
Discussion Case 4:
A rapid persistent decline in FEV1 despite interventions continues to be associated with high mortality. 52 However, recent data suggest that survival is improving in BOS. In . 54 This prospective, multi-institutional study of 36 patients showed stabilization or improvement in 94% of patients at 3 months and overall survival of 97% at 6 months. 54 Based on these results, I initiate FAM therapy for all newly diagnosed patients in addition to continuation or resumption of classical cGVHD therapy with calcinuerin inhibitor or sirolimus. The mechanistic rationale for these agents are: inhaled steroids provide local anti-inflammatory effects, azithromycin impairs interleukin-8 production and neutrophilia, and montelukast blocks leukotriene activity, impairing cellular homing and activation and possibly blocking fibroblast proliferation and collagen deposition (figure 3). 10, [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] Prior studies had showed safety and some (though not all) had suggested benefit for these agents in BOS. 63, 64, [67] [68] [69] [70] Since this trial was initiated, a prospective randomized placebo-controlled study showed efficacy for inhaled budesonide/formoterol as well, supporting the use of inhaled steroids early in BOS therapy. 71 In addition, there is a recent retrospective study on the use of budesonide/formoterol, montelukast and nacetylcysteine for BOS after HCT, which showed stabilization of FEV1, though the eligibility criteria for BOS was not the consensus definition. 72 I continue FAM components indefinitely as these have been nontoxic and, in many patients, permitted slow withdrawal of all other immunosuppression without decline in FEV1, and in some patients, even increases in FEV1. To date, the longest duration of FAM treatment for 1 7
BOS patients in my experience exceeds 10 years, supporting tolerability. However, the optimal length of treatment is unknown and will hopefully be addressed in future trials. Because of the rarity and severity of BOS after HCT, it is critically important to consider clinical trials to both better understand disease pathogenesis and identify the best therapeutic options. Currently, 13 interventional studies are listed on Clinicaltrials.gov specifically for BOS after HCT, though many have been completed (and discussed above). Studies are in development for the prevention and treatment of this disease. In addition, translational studies to identify biomarkers to predict who will develop BOS or 1 8
to identify those at high risk for progression will be invaluable. Few biomarkers have been suggested to date specifically for BOS such as serum krebs von den lungen-6 or surfactant protein D, but with the increase in trials and translational efforts, hopefully more will be forthcoming.
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Conclusions
While the pathogenesis of BOS remains poorly understood, progress has been made in the diagnosis and treatment of these patients. Consensus of diagnostic criteria has enabled interpretation of the risk factors, prognosis, supportive care, and comparison of treatment strategies. Prospective trials have shown efficacy and offered new therapies.
Incorporation of all of these advances has improved survival. However, much remains to be done in this field to better elucidate the biology underlying BOS, identify biomarkers to predict disease, develop more effective targeted therapies, monitoring for disease progression, and perhaps, in the future, allow prevention or pre-emption of BOS after HCT entirely. 
